Skip to main content
. 2010 Jan 20;17(6):1564–1571. doi: 10.1245/s10434-009-0900-z

Table 2.

Summary of published series on MVD and prognosis of HCC after resection or liver transplantation

Year of publication and Author Number of patients Therapya Microvessel stainingb Prognosis of patients with high MVDc Correlation of hypervascularity and MVDd Correlation of high VEGF and MVDe
1997 Tanigawa29 43 RES CD34 Poor (DFS/OS) NE NE
vWF
1998 El Assal25 71 RES vWF Poor (DFS) 0 0
1999 Sun30 78 RES CD34 Poor (DFS) NE NE
2002 Poon21 100 RES CD34 Poor (DFS) NE NE
vWF Poor (DFS)
2004 Nanashima31 81 RES CD34 Favorable (DFS/OS) NE NE
2005 Ho32 86 RES CD34 Comparable (DFS) NE NE
CD105 Comparable (DFS)
2006 Yang33 113 RES CD34 Comparable (OS) NE +
CD105 Poor (OS)
2006 Zhang34 82 LT CD34 Poor (DFS, univariate) NE +
2007 Yao35 105 RES CD34 Poor (DFS/OS) NE 0
CD105 Poor (DFS/OS) +
Present series 32 RES CD34 Favorable (DFS/OS) 0 (art) – (portal) NE
30 LT CD34 Comparable (DFS/OS)

NE not evaluated

aType of treatment for HCC. RES partial liver resection, LT liver transplantation

bAntibody used for detection of microvessels. vWF anti-von Willebrand factor (factor VIII), CD34 anti-CD34 antibody, CD105 anti-CD105 antibody

cPrognosis of patients with tumors with high MVD as compared to those with low MVD. DFS disease-free survival, OS overall survival

dCorrelation of hypervascularity as seen on contrast enhanced CT or angiography with MVD. +/−/0, positive, negative or no correlation

eCorrelation of vascular endothelial growth factor (VEGF) with MVD. +/−/0, positive, negative, or no correlation